Bavarian Nordic reports that it has reached another milestone in its agreement with the U.S. government and will thus receive $25 million. In June, the HHS contracted the firm to manufacture and deliver 20 million doses of its smallpox vaccine in a deal potentially worth $1.6 billion.
This year, Bavarian Nordic has received $100 million in relation to this deal. The firm was reportedly paid $50 million in advance. It also received another $25 million milestone fee just three weeks ago.
Next year, Bavarian Nordic expects to receive yet another milestone payment of $25 million.
Imvamune is based on the Modified Vaccinia Ankara virus, a live virus but one that does not replicate in the body, according to the company.